Major biotechnology companies
Profile of One of the Top Biotechnology Companies
AMGEN
Image source: View Image Source
Specialization: Human Therapeutics on cellular and molecular biology
Market Capitalization (August 2018): $204.70 billion
Assets (Dec 2025): $90.59B
Amgen is known to be one of the world’s leading biotechnology companies. The company is based in the U.S. and is primarily focused on human therapeutics based on cellular and molecular biology. It is deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
Its mission is to serve patients and dedicate its efforts to turning the tide on serious life-interrupting illnesses by pushing the boundaries of science to transform medicine.
The company has the biggest market capitalization of $204.70 billion, which indicates strong investor confidence in the biotechnology sector. Amgen’s revenues grew 4% to $6.1 billion, driven by strong double-digit volume growth from new and recently launched products including PROLIA, KYPROLIS, XGEVA, NEULASTA, and PARSABIV™.
For the fourth quarter of 2025, Amgen reported $9.9 billion in revenue, beating forecasts, with total 2025 revenues increasing 10% year-over-year. The company is now focused on innovative and differentiated medicines to address large unmet medical needs.
Biotech Products of Amgen
Neuroscience
- Aimovig – Approved in the U.S. for prevention of migraine in adults. CHMP positive opinion in EU for prevention of migraine in adults with more than 4 migraine days per month. Supplemental Biologics License Application submitted for 140mg autoinjector and prefilled syringe in the U.S.
- AMG 301 – PAC1 antibody currently in Phase 2 for migraine prevention. Data expected by year-end.
- AMG 520 (CNP520) – BACE1 inhibitor in Phase 3 for Alzheimer’s disease. Focused on treating earlier in the disease continuum. Enrolled cognitively impaired 60–75-year-olds segmented into two Generation studies: 1340 subjects with two APOE4 alleles and 2000 subjects with at least one APOE4 allele. Data expected in 2024.
Oncology
- Kyprolis – Completed enrollment in Phase 3 study of KYPROLIS® + dexamethasone (Kd) + Darzalex® vs. Kd in relapsed/refractory multiple myeloma.
- IMLYGIC – Completed enrollment in Phase 3 melanoma study in combination with Keytruda.
- BLINCYTO – Full approval in EU for adult patients with Ph- R/R B-cell precursor ALL based on TOWER OS data.
- Phase 1 Programs Advancing to Clinic: AMG 562 (CD19 HLE-BiTE®), AMG 427 (FLT3 HLE-BiTE®), AMG 424 (CD38 XmAb™), AMG 119 (DLL3 CART). Data for AMG 420 (BCMA BiTE®) and AMG 330 (CD33 BiTE®) expected by year-end.
Cardiovascular
- Repatha – New indication in EU for adults with established ASCVD to reduce cardiovascular risk by lowering LDL-C levels based on Repatha® cardiovascular outcomes study.
Bone
- Prolia – Approved in U.S. and EU for treatment of glucocorticoid-induced osteoporosis.
- Evenity – Resubmitted Biologics License Application to the FDA for treatment of osteoporosis in postmenopausal women at high risk for fracture.
Retrieved from: Official Investor Relations Page
BAYER AG
Specialization: Crop Science, Consumer Health, Pharmaceuticals
Market Capitalization (2018): $103.5 Billion
Assets: $87.35 Billion
Bayer AG is a German pharmaceutical and life sciences company with more than a 150-year history and core competencies in the areas of health and agriculture. The company is based in Leverkusen.
Primary Areas of Business:
- Pharmaceuticals: Focuses on prescription drugs in therapeutic areas such as Cardiology, Oncology, Gynecology, Hematology, and Ophthalmology.
- Consumer Health: Brings some of the most known and trusted over-the-counter medications and supplements to consumers.
- Crop Science: Operates in seeds, crop protection, and non-agricultural pest control.
- Animal Health: Supports veterinarians, farmers, and pet owners with innovative therapies and healthcare solutions.
With innovative products, Bayer is finding solutions to major global challenges. As life expectancy continues to rise, the company is creating innovative products to improve quality of life by focusing on research and development in preventing, alleviating, and treating diseases. It also works toward ensuring a reliable supply of high-quality food, feed, and plant-based raw materials.
The Pharma business posted 3% growth, mainly driven by Xarelto, Eylea, Xofigo, and Adempas. This segment remains on a positive growth trajectory.
The Crop Science division posted strong year-on-year sales growth. The Consumer Health segment was significantly impacted by Drontal and Advantage distribution in China.
Foreign exchange sensitivity remains a concern because Bayer’s products are distributed globally. Although market sentiment toward the company has been mostly negative, equity analysts perceive this as a buying opportunity, believing the stock is undervalued.
Retrieved from: Official Investor Overview
GILEAD SCIENCES, INC.
Specialization: Antiviral drugs for HIV, Hepatitis B, Hepatitis C, and Influenza
Market Capitalization (2026 est.): ~185–189 Billion
Assets: $65.36 Billion
Gilead Sciences, Inc. is a research-based biopharmaceutical company based in Foster City, California. The company focuses on treatments for HIV, hepatitis C virus (HCV), hepatitis B infection, inflammation, oncology, and serious respiratory and cardiovascular conditions.
It has become one of the largest biopharmaceutical companies in the world with a rapidly expanding product portfolio and growing pipeline of investigational drugs.
However, its HCV and other products failed to maintain strong sales momentum, leading to a decline compared to previous years. The company reported -21% growth in core revenues, and costs increased during this period.
Gilead is focusing on strengthening its HIV product portfolio. The company successfully launched Biktarvy, which has become the #1 regimen for switch patients. Based on its trajectory, it may become the #1 regimen for treatment-naïve patients and overtake Genvoya.
Biktarvy was approved in the European Union and launched in Germany and other countries. Gilead holds an 85% U.S. market share among naïve patients initiating therapy.
PrEP continues to grow in the U.S. using Truvada, the only drug indicated for HIV prevention.
The company is also engaged in the cell therapy business, with 61 cancer centers authorized in the U.S., providing access to approximately 80% of eligible patients.
Gilead received a positive opinion from CHMP for Yescarta, used in patients whose blood cancer is recurrent or refractory. Yescarta is a type of advanced therapy medicine known as a gene therapy product, delivering genes into the body to treat disease.
The company entered a cooperative research and development agreement with the National Cancer Institute to develop cell therapies targeting patient-specific tumor neoantigens. It also collaborated with Gadeta to expand its cell therapy programs.
Gilead continues to innovate in HIV through R&D programs focused on long-acting injectables, molecules for treatment-resistant HIV, and potential HIV cures.
Biktarvy is described as the “mount Everest” of HIV medicines. Based on revenue trajectory following its release, it is perceived to be more successful than Genvoya and may become the most successful HIV medicine launch in history.
Retrieved from: Official Investor Relations Page
CSL™
Specialization: Develops plasma protein biotherapies and in vitro diagnostic products
Market Capitalization (2026): $52.89 billion
Revenue: US$15.6 billion in revenue FY25
R&D investment: $643 million
CSL is a company in Melbourne, Australia that is one of the leading biotech companies that aims to save and protect people who were stricken with serious chronic medical conditions. The company develop and deliver innovative biotherapies and influenza vaccines that save lives with people who has life-threatening medical conditions.
The company develops, manufactures, and markets vaccines, plasma protein biotherapies and in vitro diagnostic products. The company has also shifted into new areas of organ transplants and gene therapy. The company is also looking to AI and big data because the company believes it might be the future we are looking to.
In their growth, Ig sales were up 13% on trailing period. Their HAEGARDA product had an exceptionally strong launch, IDELVION is fast becoming a standard of care and their specialty products of Haegarda and Kcentra were up 19% compared to previous years.
For their innovation, Product Privigen was approved for CIDP in the U.S. Hizentra was also positive CHMP recommendation for CIDP in EU. They have taken proprietary stem cell gene therapy platform through Calimmune acquisition and having an emerging transplant franchise which is the Vitaeris collaboration.
The company has launched in 13 countries their IDELVION product that counters hemophilia and they have market leadership in several countries.
For efficiency, collection center openings are now on track of their guidance and more major capital projects are now in its start-up phase like the Broadmeadows and its Kankakee base fractionation facility.
For influenza, the company’s seasonal vaccine sales are up 43% which indicates growth. Holly Springs doses quadrupled its productions. FLUAD product has now UK approval.
For the company’s financials, it posted growth of its revenues of 11% which is a good indicator of growth and Earnings per share increased by 32%.
Retrieved from: CSL Investors – Financial Results and Information
BIOGEN
Specialization: Neuroscience
Market Capitalization (2025): $28.49 billion
Revenues in 2025: $9.9 Billion
Biogen Inc. is an American multinational biotechnology company that is based in Cambridge Massachusetts specializing in the development for treatment of neurodegenerative, autoimmune and hematologic disease to patients.
It has treated millions of people around the world that are affected by multiple sclerosis, Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis.
Its core business has been stable in globe MS patients during this period compared to the previous year, the company has been developing and expanding its neuroscience portfolio by completing its phase 3 enrollment for aducanumab.
It shown positive growth in terms of revenue for its Phase 2 results for BAN2401. It has an option to acquire TMS-007 for acute ischemic stroke. And the company has acquired muscle enhancement program from AliveGen.
The company has shown progress in its R&D developments towards Alzheimer’s disease and Dementia through Aducanumab, Elenbecestat and BIIB092.
Aducanumab has demonstrated significant plaque removal as well as slowing of the cognitive decline in the phase 1b PRIME study.
Another product, which is the Elenbecestat, has demonstrated an acceptable tolerability and safety profile in its phase 2 study. Results demonstrated a statistically significant difference in β-amyloid accumulation in the brain and it has been currently being evaluated into phase 3 studies.
BIIB092 has showed Tau is hypothesized to play a distinct and complementary role in Alzheimer’s disease pathogenesis. There has already been a first patient that has been dosed in Phase 2 study for its Alzheimer’s disease.
The company has a lot of expected pipeline progress over the next 12 months.
Retrieved from: Biogen Investors – Events and Presentations
ALLERGAN PLC (Acquired by AbbVie – now an AbbVie business)
Specialization: Dermatology and Aesthetics; Central Nervous System; Eye Care; Cardiovascular and Infectious Diseases.
Market Capitalization (2025): $411.55 Billion.
AbbVie is headquartered in the United States, specifically in North Chicago, Illinois. Founded in 2013 as a spin-off from Abbott Laboratories, the company is a global biopharmaceutical firm with major research and commercial operations in the U.S. and worldwide.
It mainly focuses on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients all over the world. It has a diversified portfolio of products namely the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
The company invests in an Open Science model, where they had previously discovered, developed and delivered new products from their own labs. A large percentage of their pipeline comes from their partnership with biotech companies, academia and other pharmaceutical companies globally.
With this, the company has added product opportunities from the innovation ecosystem across their own key therapeutic areas, including Rapastinel, TrueTear, XEN Gel Stent, Cenicriviroc, Relamorelin, Ubrogepant/Atogepant and Esmya.
The company’s Vraylar and Botox Tx continue to drive sustainable growth by posting 72% and 15% growth in revenues. These products have gained market share of over 95%.
The company has also grown in its international countries by posting 11% growth during this quarter.
The company has a lot of major R&D achievements that have been accomplished. Key developments are the FDA filing of Cariprazine Bipolar Depression, BLA filing with FDA, and MAPLE study results. The company has also said that the Phase 2 of AGN-241751 has already been initiated.
The company has posted strong financial performance by having growth in revenues while maintaining strong margins.
In terms of segmented performance, US specialized therapeutics and international sales have had significant growth by posting 6.5% and 8.1% respectively.
All in all, the company remained resilient in performing its core businesses to its consumers/customers while posting growth during its performance in the past few years.
Retrieved from: Allergan Investors – Events & Presentations and AbbVie Official Website
Bristol-Myers Squibb (BMS)
Specialization: Oncology, hematology, immunology, cardiovascular, and neuroscience.
Market Capitalization (2026): $121.63 Billion
Net Product Sales: $3.8 Billion
Bristol Myers Squibb (BMS) is a leading global biopharmaceutical company headquartered in Princeton, NJ, focused on discovering and delivering innovative medicines for serious diseases in oncology, hematology, immunology, and cardiovascular areas.
Key products include Opdivo, Eliquis, and Reblozyl, with a pipeline developing treatments for schizophrenia and myeloma.
Bristol-Myers Squibb is the world's 177th most valuable company by market cap according to the data.
Its portfolio includes several FDA-approved blockbuster medicines such as Opdivo® (nivolumab) and Yervoy® (ipilimumab) for cancer immunotherapy, Eliquis® (apixaban) for anticoagulation in atrial fibrillation, and Revlimid® (lenalidomide) for multiple myeloma.
Following its acquisition of Celgene, BMS also markets Pomalyst® (pomalidomide) and Abecma® (idecabtagene vicleucel), a CAR-T cell therapy for relapsed or refractory multiple myeloma.
The company maintains an active clinical pipeline with investigational agents in Phase I–III trials targeting solid tumors, hematologic malignancies, and autoimmune disorders, including next-generation checkpoint inhibitors and cell-based immunotherapies.
Bristol-Myers Squibb maintains a strong financial position, reporting annual revenues of approximately USD 45–46 billion in FY2024, driven largely by its oncology and cardiovascular franchises such as Opdivo and Eliquis.
Despite increased R&D expenditures and integration costs from prior acquisitions (e.g., Celgene), the company continues to generate multi-billion-dollar net profits, with net income typically in the range of USD 7–8 billion annually, reflecting sustained operating margins and robust global product demand.
Retrieved from: Celgene Investor Relations
Takeda Pharmaceutical Company Ltd
Specialization: Oncology, rare diseases, gastroenterology, plasma-derived therapies, vaccines, and neuroscience.
Market Capitalization (February 2026): $58.58 Billion USD
Assets: $100.16 billion as of late 2025.
Takeda Pharmaceutical Company Limited is a Japan-based global biopharmaceutical firm specializing in oncology, rare diseases, gastroenterology, plasma-derived therapies, vaccines, and neuroscience.
Its FDA-approved products include Entyvio® (vedolizumab) for inflammatory bowel disease, Ninlaro® (ixazomib) for multiple myeloma, Adcetris® (brentuximab vedotin) for lymphoma, and immunoglobulin therapies such as HyQvia® for primary immunodeficiency.
Following the acquisition of Shire, Takeda also markets rare-disease therapies like Takhzyro® (lanadelumab) for hereditary angioedema.
In addition, Takeda maintains an active clinical pipeline with investigational biologics and gene-based therapies in Phase I–III trials targeting gastrointestinal inflammation, oncology, and rare genetic disorders.
Takeda reports annual revenues of approximately USD 28–30 billion, reflecting strong performance from its rare disease, gastroenterology, and plasma-derived therapy portfolios.
The company continues to generate multi-billion-dollar net profits, supported by global product demand and cost synergies realized following its acquisition of Shire, despite ongoing investments in R&D and debt servicing.
Retrieved from: Takeda Investors – Overview
Vertex Pharmaceuticals
Specialization: Treatment for Cystic Fibrosis and Other Life-Threatening Diseases
Market Capitalization as of August 2018: $45.193 Billion
Assets: $2.7 B (as of Q2, 2018)
Vertex was founded in 1989 in Cambridge Massachusetts and is headquartered in Boston, with an international headquarters in London, United Kingdom.
Its stock is traded on the NASDAQ stock exchange with the ticker: VRTX.
Growth increase is driven by rapid uptake of newly launched SYMDEKO in the US and an increase in net product revenues for KALYDECO and ORKAMBI.
The company improved margins despite an increase in R&D expenses as well as SG&A expenses. This advancement is due to the company’s growing portfolio supporting Cystic Fibrosis treatments globally.
SYMDEKO experienced strong demand after its launch, including approval from Canada and EU.
Vertex also highlights its partnership with CRISPR Therapeutics after obtaining approval in the UK for a Clinical Trial Application (CTA) for CTX001, a treatment for Beta Thalassemia.
As of 18–19 February 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) is trading at approximately USD 470–495 per share, with the latest closing price reported around USD 470.31.
Retrieved from: Vertex Investor Relations – Financial Results
Regeneron Pharmaceuticals
Specialization: Treatment for Retinal Diseases and Atopic Dermatitis
Market Capitalization as of August 2018: $83.86 Billion
Assets: $40.56 billion (2025)
Regeneron was founded in 1988 by Leonard S. Schleifer, MD, PhD, a neurologist and assistant professor at Cornell University Medical College.
The company began trading on the NASDAQ stock exchange in 1991, where its Initial Public Offering (IPO) raised $91 million.
In 2017, Regeneron highlighted its fifth and sixth FDA-approved medicines: DUPIXENT and KEVZARA injections.
Major products include EYLEA (aflibercept) for eye diseases, Dupixent (dupilumab) for allergic/inflammatory conditions, Libtayo (cemiplimab) for cancer, Praluent (alirocumab), Evkeeza (evinacumab), and Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn).
The company is known for its VelociSuite® technologies and has 13 approved medicines in the U.S. or other countries.
Headquartered in Tarrytown, NY, the company focuses on homegrown innovation.
Regeneron maintains a strong financial position, with 2025 full-year revenues reaching $14.3 billion, a 1% increase, driven by growth in Dupixent and EYLEA HD.
As of February 2026, the company has a market cap of approximately $84.9 billion, supported by consistent, high-demand product sales.
Retrieved from: Regeneron Investor Relations
Jiangsu Hengrui Medicine
Specialization: Largest manufacturer of antineoplastics in China
Market Capitalization as of August 2018: $27.90 Billion
Jiangsu Hengrui Medicine Co., LTD is a Chinese company focused on manufacturing and distribution of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, among others with their distribution reaching both domestic and overseas markets.
Its stock is traded in the Shanghai Stock Exchange under the ticker: 600276.
Recent highlights include receiving FDA approval for desflurane for inhalation and Dexmedetomidine Hydrochloride Injection, enabling the company to sell these products in the US. The approvals were granted in March 2018 and November 2017, respectively.
Trials were also approved for their drug Seebri® Breezhaler® by the Chinese Food and Drug Administration.
In terms of Financial Highlights, their net income growth stands at 24.5% over the past 5 years.
The company exhibits stronger ratios compared to industry averages based on Reuters reports:
P/E ratio: 69.58 compared to industry average of 29.46
ROI: 23.37% (5-year average) compared to industry 15.08%, indicating higher returns on investments than the industry average.
Profitability ratios such as Operating Profit Margin, Net Profit Margin, and Gross Margin all exceed industry averages, demonstrating competitive performance and overall profitability.
Retrieved from: Reuters – Key Developments and Reuters – Financial Highlights
Samsung Biologics
Specialization: Biopharmaceutical manufacturing
Market Capitalization as of August 2026: $55.39 Billion USD
Assets (2026): $13.06 Billion USD
Samsung Biologics is a South Korean firm based in Incheon, founded in April 2011 as a joint venture between Samsung affiliate companies and Quintiles Transnational Corp.
The company is considered a Contract Manufacturing Organization (CMO) manufacturing antibody drugs for auto-immune diseases, cancer, diabetes, and related conditions.
Samsung Biologics does not market proprietary therapeutics but manufactures multiple FDA-approved biosimilars developed by its affiliate Samsung Bioepis, including infliximab, trastuzumab, adalimumab, ranibizumab, and eculizumab biosimilars.
Additional oncology monoclonal antibodies are currently in late-phase clinical development.
The company has expanded its CDMO operations significantly since 2018, with a contracted backlog exceeding KRW 12–15 trillion (≈ USD 9–11 billion) through long-term biologics manufacturing agreements with global pharmaceutical companies, including expanded MSAs with firms such as UCB.
Total manufacturing capacity has reached approximately 784,000 liters following commissioning of Plant 4, making it the world’s largest single-site biologics manufacturing facility.
In FY2024, Samsung Biologics reported revenues of KRW 3.7–3.9 trillion (≈ USD 2.8–3.0 billion) and operating profits exceeding KRW 1 trillion (≈ USD 750–800 million).
Retrieved from: Samsung Biologics – Company Overview
Alexion Pharmaceuticals
Specialization: Enzyme Replacement Therapies and development of the world's first approved terminal complement inhibitor
Market Capitalization (2026): $26.18 Billion / $40.33 Billion
Assets (2026): US$18.103 billion
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a Boston-based biopharmaceutical company focused on developing therapies for rare and devastating disorders.
Founded in 1992, it is a leader in complement system research, offering products like Ultomiris and Soliris for hematology, nephrology, and neurology conditions.
Key FDA-approved products include Soliris® (eculizumab) and Ultomiris® (ravulizumab) for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Other products include Strensiq® (asfotase alfa) for hypophosphatasia and Kanuma® (sebelipase alfa) for lysosomal acid lipase deficiency.
Ultomiris generated approximately USD 3.9 billion in global sales in 2024, while Soliris contributed about USD 2.5 billion despite biosimilar competition.
Alexion was acquired by AstraZeneca in 2021 for approximately USD 39 billion, after which its shares were delisted from NASDAQ and no longer trade publicly as ALXN.
Prior to acquisition, the deal valued Alexion stock at approximately USD 175 per share, representing its last effective trading benchmark.
Retrieved from: Alexion Investor Report and Reuters – Alexion Financial Highlights
Teva Pharmaceutical Industries Ltd.
Specialization: Products that address respiratory diseases
Market Capitalization as of August 2018: $40.43 Billion
Assets (2025): $40.75 billion USD
Established in Jerusalem in 1901, the company known today as Teva started as a small wholesale drug business distributing imported medications. Originally named S.L.E after its founders Chaim Salomon, Moshe Levin, and Yitschak Elstein, it served as the sole source of pharmaceutical supplies for the local market, neighboring countries, and the British Army stationed in the Middle East during World War II.
A consolidation period in the Israeli pharmaceutical industry during the 1960s culminated in the 1976 union of Teva, Assia, and Zori, creating Israel’s largest drugmaker.
Teva expanded internationally in 1980, entering the US market and later becoming a global leader through major acquisitions across Canada, the US, and Europe, with subsidiaries in Latin America.
Today, Teva is known as the world’s largest medicine cabinet, providing medicines to approximately 200 million people daily across about 100 global markets with a portfolio of 16,000 products.
Teva markets a wide range of generic medicines in central nervous system disorders, cardiovascular disease, oncology, respiratory care, and anti-infectives.
Key FDA-approved specialty products include Copaxone® (glatiramer acetate) for multiple sclerosis, Austedo® (deutetrabenazine) for Huntington’s disease–related chorea and tardive dyskinesia, and Ajovy® (fremanezumab) for migraine prevention.
Retrieved from: Teva Official Website
Sun Pharmaceutical Industries
Specialization: Generic products targeting a wide spectrum of chronic and acute treatments
Market Capitalization (2025): £33.66 Billion
Assets (2025): $11 billion USD
Sun Pharma was established in 1961 by Ranbaxy, beginning with five products and a two-person marketing team. In 1985, it set up the Ranbaxy Research Foundation and launched its IPO a decade later, expanding sales to 24 countries.
It entered the US market with branded products and became one of the fastest-growing pharmaceutical companies in the early 2000s, surpassing $100 million and later $1 billion in US sales.
In 2007, Sun Pharma formed the Sun Pharma Advanced Research Company (SPARC), the first research company listed on the Indian Stock Market.
Sun Pharma acquired 14 brands from Novartis (Japan), collaborated with institutes specializing in brain therapies, and launched Imatinib Mesylate.
The company manufactures and markets generic and specialty pharmaceutical products in dermatology, oncology, ophthalmology, cardiology, psychiatry, anti-infectives, and active pharmaceutical ingredients (APIs).
Sun Pharma increasingly focuses on high-margin innovative medicines in dermatology, oncology, and chronic disease management.
It reported FY 2025 revenues of approximately USD 6.2–6.4 billion, with continued year-on-year growth driven by strong domestic and specialty drug sales.
Retrieved from: Sun Pharma – Milestones
Mylan
Specialization: Oral solid dosages, injectables, transdermal patches, gels, creams and ointments
Market Capitalization (2025): $18.13 Billion
Revenues in 2020: $11.50 billion
Mylan started in 1961 in West Virginia and began manufacturing products in 1966 in Morgantown, West Virginia.
It evolved into a global pharmaceutical organization focused on expanding access to medicines worldwide, serving approximately 7 billion individuals.
Mylan (now part of Viatris Inc.) markets a broad portfolio of generic and specialty pharmaceuticals across cardiovascular disease, central nervous system disorders, infectious diseases, oncology, respiratory care, and biosimilars such as insulin glargine and trastuzumab.
Following its merger with Upjohn (a Pfizer division), the combined company reported annual revenues of approximately USD 14–15 billion.
The company maintains steady profitability supported by emerging market demand and cost-efficient large-scale manufacturing.
Mylan offers approximately 7,500 products globally, including antiretroviral treatments relied upon by over 40% of individuals living with HIV/AIDS worldwide.
The company operates in over 165 countries and is one of the world’s largest producers of active pharmaceutical ingredients and devoted to making better wellbeing for a better world by treating one person at a time.
Retrieved from: Mylan – Business Segments
INCYTE
Specialization: Oncology (study and treatment of tumors)
Market Capitalization (2026): $20.12 Billion USD
Assets (2026): $6.33 Billion USD
Incyte, established in 2002 and headquartered in Delaware, U.S., is a biopharmaceutical company focused primarily on oncology and inflammatory diseases.
Incyte markets several products, including its flagship drug Jakafi® (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease.
It also markets Opzelura® (ruxolitinib cream) for atopic dermatitis and vitiligo.
In addition, Incyte collaborates on partnered therapies such as Pemazyre®, Monjuvi®, Tabrecta®, and Olumiant®.
The organization employs more than 1,200 individuals across the United States, Europe, and Japan and further strengthened its inflammatory disease pipeline in 2024 through the USD 750 million acquisition of Escient Pharmaceuticals.
Retrieved from: https://www.incyte.com/who-we-are/biopharmaceutical-research
KANGMEI PHARMACEUTICAL
Specialization: Various Chinese medicines
Market Capitalization (2026): $3.7–3.9 billion
Assets (2026): $1.9–2.0 billion USD
Kangmei Pharmaceutical Co., Ltd is a China-based organization founded in 1997 and headquartered in Puning, China. The company is primarily engaged in the manufacturing and sales of various Chinese pharmaceutical products and operates its own hospital offering the products that it produces.
The company's main products include Chinese prescriptions such as American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, malti flower (Chinese honeysuckle or Rangoon creeper), knotweed, angelica, lonicera bloom, Ganmaoling Granule, and Qingkailing Capsules.
Kangmei Pharmaceutical Co., Ltd focuses on conducting business within domestic markets and regional clients.
Financially, Kangmei reported FY2024 revenues of approximately CNY 5.19 billion (≈ USD 716–730 million), reflecting modest year-on-year growth of about 6.5%. However, its net income declined significantly in 2024, indicating continued financial recovery challenges following prior regulatory and accounting issues, despite ongoing operational reforms.
Retrieved from: https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=12709357
YUNNAN BAIYAO GROUP
Specialization: Traditional Chinese medicine
Market Capitalization (2026): $100.81B
Assets (2024-25): $7.2 Billion USD
Yunnan Baiyao Group Co., Ltd, based in Kunming, China, is a Chinese pharmaceutical organization that creates and manufactures pharmaceutical items (mostly Traditional Chinese medicines) and offers wholesale and retail pharmaceutical products both domestically and internationally.
The company develops and markets a wide range of traditional Chinese medicines (TCMs), phytobiological products, wound-healing formulations, antibiotics, anti-inflammatory drugs, and consumer health products such as herbal toothpaste and topical plasters.
Its flagship product line includes the Yunnan Baiyao series, widely used for hemostatic and anti-inflammatory purposes in both clinical and OTC settings.
The Yunnan Baiyao series includes powders, capsules, plasters, wound plasters, and mist concentrates for activating blood circulation, reducing swelling, mitigating pain, and treating traumatic and cold wounds.
The company also offers phytobiological solutions in oral fluids, tablets, powders, flower-leaf granules, and capsules, as well as wellness products such as toothpaste, skin relief products, shoe disinfectant aerosols, and first aid kits.
Furthermore, the organization produces products such as paracetamol, aminophenazone, caffeine, chlorphenamine maleate tablets, oxytetracycline tablets, and norfloxacin capsules. Its portfolio includes Yunnan Bai Yao biotechnological research products and the Natural Vegetable series.
The company is also involved in operating hotels and retail establishments.
Financially, Yunnan Baiyao reported annual revenues of approximately USD 5.5–5.7 billion, total assets of about USD 7–7.9 billion, and net profits around USD 650–700 million in recent fiscal reporting periods.
As of February 2026, Yunnan Baiyao has a market capitalization of roughly CNY 100–101 billion (≈ USD 14–15 billion), reflecting its strong domestic pharmaceutical market presence.
Retrieved from: https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=6476754
SHANGHAI FOSUN PHARMACEUTICAL GROUP
Specialization: Oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system, and anti-infection
Market Capitalization (2026): $75.17 Billion
Assets: $16.2 Billion USD
Shanghai Fosun International Group was established in 2016 in Shanghai, China. The company integrates global industries and is committed to becoming a first-tier enterprise in the global mainstream pharmaceutical and healthcare market.
In March 2017, the company acquired Breas, a Swedish professional respiratory medical device company. Later in 2017, the organization established an innovation incubation platform called Fosun Lead, listed on the main board of the Hong Kong Stock Exchange, completed a 74% equity acquisition of Gland Pharma, established the Suzhou Innovation R&D Center, and initiated manufacturing of the FDA-approved CAR-T product Yescarta in China through Fosun Kite, following the Chinese regulatory pathway.
In December 2017, the company also acquired an 82% stake in Tridem Pharma, a French pharmaceutical distribution and promotion company.
Within just two years, the company entered the top 20 among hundreds of global biotech companies.
The company markets a broad portfolio of biopharmaceuticals, small-molecule drugs, medical devices, vaccines, and diagnostic products. Its therapeutic focus areas include oncology, infectious diseases, cardiovascular disorders, and central nervous system conditions.
Its commercialized products include innovative monoclonal antibodies, antiviral agents, oncology therapeutics, biosimilars, licensed vaccines, and COVID-19–related biologics through global partnerships.
Financially, Fosun Pharma reported annual revenues of approximately USD 5.8–6.2 billion, supported by steady growth in both its pharmaceutical manufacturing and healthcare services segments.
The company maintains total assets exceeding USD 15–17 billion and continues investing in research and development, as well as international expansion across emerging and developed markets.
Fosun Pharma holds leading positions in therapeutic areas including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system, and anti-infection.
Retrieved from: Source Here
Additional Resources
- Largest Biotech Companies by Market Cap – Check Here
- List of Biotechnology Companies – Check Here
- Top 25 Biotech Companies Heading into 2026 – Check Here
Top Biotechnology companies in the world (ranking year: 2024) Source
Philippidis A. Top 25 Biotech Companies Heading Into 2025: Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show gains: Market capitalization of the largest public biotech companies jumps nearly 12% yearover-year, as all but five of them show gains. Genetic Engineering & Biotechnology News. Check Here